Catalyst Wire Dossier Catalyst Wire Dossier

OMS906

OMS906 · Omeros Corporation
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for OMS906, covering 2025-07-15 to 2025-10-01. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab [Phase 2]

See pricing